drugs regulatory system'
by Angela Hussain
group of MPs have called for the "lax" pharmaceutical
regulatory regime to be overhauled, saying it has prioritised the
interests of the industry over public safety.
reactions caused by a number of drugs, such as the antidepressant
Seroxat, have revealed fundamental flaws in the regulatory system,
a report published last week by the health select committee said.
report read: "An effective regulatory regime to ensure the
industry works in the public interest is essential. Unfortunately
the present regulatory system is failing to provide this."
called for a wholesale review of the Medicines and Healthcare products
Regulatory Agency, saying it has grown too close to industry and
inadequately scrutinised clinical trials for Seroxat and other drugs.
also called for sponsorship of the industry to be transferred from
the Department of Health (DoH) to the Department of Trade and Industry,
saying the DoH had let companies' interests override its responsibilities
has also recommended that all clinical trial results to be put on
an independent register before companies are given a licence to
Corlett, mental health charity MIND's director of policy, said:
must now put in place a drug regulation system that prioritises
Committee's report on the influence of the pharmaceutical industry
2, 2005: 'SSRI antidepressants are safe' drugs regulator repeats
to doctors - publication of research linking suicidal behaviour
to SSRIs prompts reaction by MHRA.
6, 2004: No evidence that SSRI antidepressants likely to increase
suicidal behaviour, watchdog announces - NICE guidelines also
issued for treatment of depression
do you think? Email your comments on the above
article to the editor using the form below. Selected comments will
© 2001-7 Psychminded Limited. All
about this article